scholarly journals Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study

Diabetes Care ◽  
2021 ◽  
pp. dc203133
Author(s):  
Min-Kyung Lee ◽  
Bongsung Kim ◽  
Kyungdo Han ◽  
Jae-Hyuk Lee ◽  
Minhee Kim ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Propensity Score ◽  
Retinal Vein Occlusion ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Vein Occlusion ◽  
Sodium Glucose Cotransporter

scholarly journals Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study

2021 ◽  
Author(s):  
Min-Kyung Lee ◽  
Bongsung Kim ◽  
Kyungdo Han ◽  
Jae-Hyuk Lee ◽  
Minhee Kim ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Retinal Vein Occlusion ◽  
Sglt2 Inhibitors ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Vein Occlusion ◽  
Sodium Glucose Cotransporter ◽  
Increased Risk ◽  
Subgroup Analyses

<b>OBJECTIVE</b><b></b> <p>To assess the association between use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and retinal vein occlusion (RVO) using data from the National Health Insurance Service in South Korea.</p> <p><b>RESEARCH DESIGN AND METHODS</b><b></b></p> <p>We used an active comparator, new user design and nationwide data from 2014 to 2017. Based on a 1:1 propensity score match, we included 47 369 new users of SGLT2 inhibitors and 47 369 users of other glucose-lowering drugs (oGLD). In the matched sample, we used the Cox proportional hazards model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for developing RVO. Based on the main outcome, exploratory subgroup analyses were undertaken.</p> <p><b>RESULTS</b></p> <p>During the follow-up of 2.57 years, the incidence rate of RVO was 2.19 and 1.79 per 1000 person-years in patients treated with SGLT2 inhibitors and oGLD, respectively. The new use of SGLT2 inhibitors was associated with an increased risk of RVO compared with oGLD use (HR 1.264, 95% CI 1.056–1.513). In the subgroup analyses, a significant interaction with SGLT2 inhibitors was observed for <em>age and estimated glomerular filtration rate (eGFR);</em> the HR for RVO was higher in patients aged ≥ 60 years and those with eGFR <60 mL/min/1.73m<sup>2</sup> than in others.</p> <p><b>CONCLUSIONS</b></p> <p>In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of RVO. The older patients and those with chronic kidney disease were at higher risk for RVO. </p>

scholarly journals Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study

2021 ◽  
Author(s):  
Min-Kyung Lee ◽  
Bongsung Kim ◽  
Kyungdo Han ◽  
Jae-Hyuk Lee ◽  
Minhee Kim ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Retinal Vein Occlusion ◽  
Sglt2 Inhibitors ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Vein Occlusion ◽  
Sodium Glucose Cotransporter ◽  
Increased Risk ◽  
Subgroup Analyses

<b>OBJECTIVE</b><b></b> <p>To assess the association between use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and retinal vein occlusion (RVO) using data from the National Health Insurance Service in South Korea.</p> <p><b>RESEARCH DESIGN AND METHODS</b><b></b></p> <p>We used an active comparator, new user design and nationwide data from 2014 to 2017. Based on a 1:1 propensity score match, we included 47 369 new users of SGLT2 inhibitors and 47 369 users of other glucose-lowering drugs (oGLD). In the matched sample, we used the Cox proportional hazards model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for developing RVO. Based on the main outcome, exploratory subgroup analyses were undertaken.</p> <p><b>RESULTS</b></p> <p>During the follow-up of 2.57 years, the incidence rate of RVO was 2.19 and 1.79 per 1000 person-years in patients treated with SGLT2 inhibitors and oGLD, respectively. The new use of SGLT2 inhibitors was associated with an increased risk of RVO compared with oGLD use (HR 1.264, 95% CI 1.056–1.513). In the subgroup analyses, a significant interaction with SGLT2 inhibitors was observed for <em>age and estimated glomerular filtration rate (eGFR);</em> the HR for RVO was higher in patients aged ≥ 60 years and those with eGFR <60 mL/min/1.73m<sup>2</sup> than in others.</p> <p><b>CONCLUSIONS</b></p> <p>In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of RVO. The older patients and those with chronic kidney disease were at higher risk for RVO. </p>

scholarly journals Effectiveness of monthly and bimonthly follow-up of patients with well-controlled type 2 diabetes: a propensity score matched cohort study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Tomohiko Ukai ◽  
Shuhei Ichikawa ◽  
Miho Sekimoto ◽  
Satoru Shikata ◽  
Yousuke Takemura
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Propensity Score ◽  
Matched Cohort ◽  
Matched Cohort Study
Sign in / Sign up

Export Citation Format

Share Document